Related Experiment Video
Updated: May 24, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials
Bill Byrom1, Anthony Everhart1, Paul Cordero2
1Science and Medicine, Signant Health, 785 Arbor Way, Blue Bell, PA, 19422, United States, 44 20 4526 1340.
Unlabelled:
While patient-reported outcome measures are regularly incorporated into phase 3 clinical trials, they have been infrequently used in early phase trials. However, the patient's perspective is vital to fully understanding dose toxicity and selecting an optimal dose. This viewpoint paper reviews the rationale for and practical approach to collecting patient-reported outcome data in early phase oncology drug development and the rationale for electronic collection.
Related Concept Videos
Clinical Trials: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Survival Analysis
Clinical Trials
There are four phases in a clinical trial. A phase one...

